IQ-AI Limited IB Opens Expanded Access Program

RNS Number : 7858T

IQ-AI Limited

25 June 2024

 

June 25, 2024

IQ-AI Ltd

("IQ-AI" or the "Company")

 

Imaging Biometrics Opens Expanded Access Program

New cancer treatment with the potential to slow brain tumor growth is now available to patients in the US with relapsed/refractory histologic or molecular glioblastoma

Imaging Biometrics, LLC ("IB"), the Wisconsin USA based subsidiary of IQ-AI (LSE: IQAI), announces that the US Food and Drug Administration ("FDA") has approved an Expanded Access Program ("EAP") for oral gallium maltolate ("GaM").

This EAP will run in parallel with the current phase 1 clinical trial being conducted at the Medical College of Wisconsin ("MCW"). As the phase 1 trial concludes this fall and while the data is being compiled, eligible patients in the US will have the option of participating in the EAP. Several patients have registered to participate in the EAP, and a total of 40 patients can enrol in this initial phase.

"Providing eligible patients access to GaM as a potential treatment ahead of regulatory approval underscores our commitment to helping address a clear unmet patient need," said Trevor Brown, CEO of IQAI.

 

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

For further information, please contact:

 

IQ-AI Ltd Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda Tel: [phone]

Peterhouse Capital Limited (Financial Adviser and Broker) Lucy Williams/Heena Karani Tel: [phone]

About Imaging Biometrics® LLC:  IB is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com. Follow IB on Twitter, @IQAI_IB.  

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

STRVELBLZQLEBBQ